
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)*

Century Therapeutics, Inc.

(Name of Issuer)

Common Stock, \$0.0001 par value per share

(Title of Class of Securities)

15673T100

(CUSIP Number)

03/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
 Rule 13d-1(c)
 Rule 13d-1(d)
-

SCHEDULE 13G

CUSIP No. 15673T100

Names of Reporting Persons

1

Casdin Capital, LLC

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

DELAWARE

	Sole Voting Power
5	0.00
Number of Shares Beneficially Owned by Each Reporting Person With:	Shared Voting Power
6	3,212,316.00
	Sole Dispositive Power
7	0.00
	Shared Dispositive Power
8	3,212,316.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person
	3,212,316.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	<input type="checkbox"/>
11	Percent of class represented by amount in row (9)
	3.7 %
12	Type of Reporting Person (See Instructions)
	IA

SCHEDULE 13G

CUSIP No. 15673T100

1	Names of Reporting Persons
	Eli Casdin
	Check the appropriate box if a member of a Group (see instructions)
2	<input type="checkbox"/> (a)
	<input type="checkbox"/> (b)
3	Sec Use Only
4	Citizenship or Place of Organization
	UNITED STATES
	Sole Voting Power
5	0.00
Number of Shares Beneficially Owned by Each Reporting Person With:	Shared Voting Power
6	3,212,316.00
	Sole Dispositive Power
7	0.00
	Shared Dispositive Power
8	3,212,316.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person
	3,212,316.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	<input type="checkbox"/>

11 Percent of class represented by amount in row (9)
3.7 %
Type of Reporting Person (See Instructions)

12 HC, IN

SCHEDULE 13G

Item 1.

Name of issuer:

(a) Century Therapeutics, Inc.

Address of issuer's principal executive offices:

(b) 25 North 38th Street, 11th Floor, Philadelphia, Pennsylvania 19104

Item 2.

Name of person filing:

(a) Casdin Capital, LLC Eli Casdin

Address or principal business office or, if none, residence:

(b) Casdin Capital, LLC 1350 Avenue of the Americas, Suite 2600 New York, New York 10019 Eli Casdin 1350 Avenue of the Americas, Suite 2600 New York, New York 10019

Citizenship:

(c) Casdin Capital, LLC - Delaware Eli Casdin - United States

Title of class of securities:

(d) Common Stock, \$0.0001 par value per share

CUSIP No.:

(e) 15673T100

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

- (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
- (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e) An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
- (f) An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
- (g) A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
- (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in
- (j) accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
- (k) Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4. Ownership

Amount beneficially owned:

(a) Casdin Capital, LLC - 3,212,316 Eli Casdin - 3,212,316

Percent of class:

(b) Casdin Capital, LLC - 3.7% Eli Casdin - 3.7% %

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

Casdin Capital, LLC - 0 Eli Casdin - 0

(ii) Shared power to vote or to direct the vote:

Casdin Capital, LLC - 3,212,316 Eli Casdin - 3,212,316

(iii) Sole power to dispose or to direct the disposition of:

Casdin Capital, LLC - 0 Eli Casdin - 0

(iv) Shared power to dispose or to direct the disposition of:

Casdin Capital, LLC - 3,212,316 Eli Casdin - 3,212,316

Item 5. Ownership of 5 Percent or Less of a Class.

Ownership of 5 percent or less of a class

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

All of the securities reported in this Schedule 13G are directly owned by advisory clients of Casdin Capital, LLC. None of those advisory clients may be deemed to beneficially own more than 5% of the Common Stock, \$0.01 par value.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Casdin Capital, LLC

Signature: /s/ Eli Casdin

Name/Title: Eli Casdin / Managing Member

Date: 05/15/2025

Eli Casdin

Signature: /s/ Eli Casdin

Name/Title: Eli Casdin

Date: 05/15/2025

Comments accompanying signature: * Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his, her or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or

for any other purpose. To the extent that "ownership of 5 percent or less of a class" was indicated in Item 5, such response only applies to the Reporting Person(s) that indicated elsewhere herein that it beneficially owns five percent (5%) or less of the class.

Exhibit Information

Exhibit A - Joint Filing Agreement

JOINT FILING AGREEMENT

The undersigned agree that this Schedule 13G Amendment No. 1 dated May 15, 2025 relating to the Common Stock, \$0.0001 par value per share, of Century Therapeutics, Inc. shall be filed on behalf of the undersigned.

CASDIN CAPITAL, LLC

By: /s/ Eli Casdin

Name: Eli Casdin

Title: Managing Member

ELI CASDIN

By: /s/ Eli Casdin
